Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 31.78% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 90.50M.
Overvalued
The company’s latest PE is -1.14, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 36.92M shares, decreasing 13.38% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 83.73K shares of this stock.